Deals In Depth: December 2013
Executive Summary
Following the loss of patent protection on its antidepressant Lexapro in 2012, Forest added a new drug to its neurology portfolio, licensing US rights to Merck’s antipsychotic Saphris for $240 million; AstraZeneca took full control of BMS’s global diabetes business, paying $2.9 billion up front. Financing in December lagged behind the previous month’s figures in both biopharma and device.